FUZION is the first and only randomized, controlled trial to show efficacy of an IL-23p19 antagonist in perianal fistulizing Crohn’s disease and the first trial of any therapy for perianal Crohn's disease since 1999.
FUZION is the first and only randomized, controlled trial to show efficacy of an IL-23p19 antagonist in perianal fistulizing Crohn’s disease and the first trial of any therapy for perianal Crohn's disease since 1999.
FUZION is the first and only...